Lyman BioPharma Consulting LLC

Advice and Resources for the Biotech Industry

Advice and Resources for the Biotech Industry

Stacks Image 4233

Opinion-Editorial Articles (and Podcasts)

“Data Irreproducibility: The “Waste, Fraud, and Abuse” of Scientific Research” BioPharma Observer Feb. 12, 2018

“Is Pharma Really Facing It’s Demise?” BioPharma Observer Jan. 22, 2018

“What to Read to Get the Latest BioPharma/Healthcare Info” BioPharma Observer Dec. 11, 2017

“Non-Compete Agreements: Dangerous Liaisons” BioPharma Observer Nov. 13, 2017

“Sci-Hub vs. iPubSci: Another Look at Accessing Unaffordable Science Journals” BioPharma Observer Oct. 16, 2017

“Health Insurance Improves Patients Lives” BioPharma Observer Sept. 21, 2017

“Rock Lyrics Predicted Drug Discoveries” BioPharma Observer August 15, 2017

“BioPHarma Haiku Round 4” BioPharma Observer July 11, 2017

“Summer Reading List 2017: Even More True Tales to Inform and Amuse You” BioPharma Observer June 6, 2017

“So What Did the March for Science Accomplish?” BioPharma Observer May 2nd, 2017

“President Puts America’s Freedoms in Peril”
Albany Times Union April 15, 2017

“12 Lessons Learned from My Cancer Diagnosis” Patient Power website, April 6, 2017

“Why I’m Joining in the March for Science” BioPharma Observer March 7, 2017

“BioPharma and Hollywood: Land of the Blockbusters” BioPharma Observer Feb. 21, 2017

“Hollywood and BioPharma: Differentiated by Unique Economic Models” BioPharma Observer Feb. 21, 2017

“Would Government Buyouts of Pharma Companies Really Be A Good Way To Lower Drug Prices?” BioPharma Observer Feb. 7, 2017

“Consequences: In a Post-Truth World, Scientific Progress Goes Boink” BioPharma Observer Jan. 17, 2017